Role of Trp and Phe gut-dependent Microbiota Metabolites in Atherosclerosis – MIMEA

The prevalence of Western diet-induced metabolic syndrome is booming contributing to persist increase of cardiovascular diseases (CVD), including atherosclerosis. Many patients with obesity suffer from adverse metabolic complications and associated atherosclerosis, whereas other remain metabolically healthy. Thus, understanding the pathogenesis of these associated diseases and identifying new therapeutic targets is of utmost importance. The aim of the present research is to characterize tryptophan and phenylalanine gut-dependent metabolites playing important roles in atherosclerosis by using “metabolomics” approaches. To this end, a combination of NRM (profiling) and Mass (targeted) metabolomics approaches will be used on mouse models of atherosclerosis and on human samples from general population. This strategy will allow us to identify and validate metabolites that can be considered as a basis for the development of new treatments of western life style-associated diseases.